PBYI - pumabiotechnology.com Operating profit EBITDA

Debt obligations and the risk of generic competition constrain the investment potential of Puma Biotechnology (PBYI). However, the exclusive targeted therapy Nerlynx effectively captures the HER2-positive cancer treatment niche, while stable sales ensure a steady inflow of funds. The absolute EBITDA trend on GURU.Markets confirms the resilience of the cash flow, while the 40.96 metric indicates the current scale of the company's operating profit.

Puma Biotechnology's stable patient base and the expansion of therapeutic indications are reflected in the EBITDA_Co level on this chart, demonstrating the actual scale of operating cash flow. This metric measures earnings before depreciation, interest, and taxes, allowing investors to assess the efficiency of the core business regardless of debt load, which is critical for analyzing the company's resilience in a mature segment.